Product/Composition:- | Torsemide injection |
---|---|
Strength:- | 10 mg/mL. |
Form:- | Injection |
Reference Brands:- | Demadex(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Torsemide injection is a loop diuretic that inhibits the sodium-potassium-chloride co-transporter in the kidneys, leading to increased urine output. It rapidly reduces fluid overload, edema, and blood pressure. Benefits include quick symptom relief, improved cardiac and renal function, and effective fluid management in acute heart failure and edema.
Torsemide injection, marketed as Demadex, is approved in the US by the FDA and in the EU via EMA for edema and heart failure management requiring rapid diuresis. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market entry strategies, visit PharmaTradz. Ensuring regional compliance is critical for timely approval, safe use, and global availability, supporting effective management of fluid overload and cardiovascular health worldwide.